Net sales grew 12.9% year-over-year in Q2 2026, with strong gains in both consumer and healthcare segments. Operating profit and net income increased, supported by new contracts and higher prescription drug sales. Solid financial position and positive outlook, despite ongoing market and supply risks.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.